Moshe C. Ornstein MDGenitourinary Medical Oncologist, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
Dr. Moshe Ornstein is a genitourinary medical oncologist at the Cleveland Clinic Taussig Cancer Institute. He attended graduate school at Columbia University, where he received a degree in biotechnology studying tumor immunology. Following graduate school, he attended medical school at SUNY Stony Brook. His completed his internal medicine residency and hematology/oncology fellowship at the Cleveland Clinic.
Dr. Ornstein's clinical practice and research are focused on cancers of the genitourinary system, specifically kidney, bladder, and prostate cancer. He has published multiple research articles and presented his research at a variety of national meetings, including the annual meeting of the American Society of Clinical Oncology (ASCO) and ASCO Genitourinary Cancers Symposium. He is actively involved in multiple clinical trials.
Dr. Ornstein reports the following disclosure: Consulting/Advisory Role: Pfizer, Eisai, BMS; Speaking: BMS, Exelixis.
Recent Contributions to PracticeUpdate:
- Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma
- ASCO GU 2016: Dr. Fred Saad’s Prostate Cancer Year in Review—Part 1: Screening and Active Surveillance
- ASCO GU 2016: Dr. Fred Saad’s Prostate Cancer Year in Review—Part 3: ADT, Chemotherapy in Hormone-Sensitive Disease, and New Options in mCRPC
- ASCO GU 2016: Dr. Fred Saad’s Prostate Cancer Year in Review—Part 2: Importance of Local Therapy
- Pneumonitis in Patients Receiving Anti-PD-1/PD-L1 Therapy
- IKCS 2015: mRCC Tumor Burden Reduced With TKI Dose Escalation
- Dr. Mary-Ellen Taplin’s “Do Not Miss” GU Oncology Highlights of 2014
- Controversy at ASCO GU: Conflicting Randomized Trials on Docetaxel Plus ADT for Hormone Sensitive Metastatic Prostate Cancer
- The Utility of Biopsy and Role of Cryoablation vs Partial Nephrectomy
- Blood Pressure After Acute Intracerebral Hemorrhage